stockrow
Friday 6 November 2026
Export VCEL’s income statement to Excel — free account
Vericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
54.39
2.61
+5.04%
Follow VCEL
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
60.82 | 92.69 | 74.81 | 112.53 |
+8 more quarters Free account |
P/S ratio |
6.34 | 7.42 | 5.59 | 6.56 | |
P/FCF ratio |
35.49 | 36.85 | 34.40 | 73.25 | |
P/Operating CF |
115.93 | 140.35 | 99.70 | 120.74 | |
P/B ratio |
5.35 | 6.14 | 4.59 | 5.11 | |
Price to Tangible BV |
5.42 | 6.23 | 4.66 | 5.19 | |
EV/Sales |
5.87 | 6.94 | 5.15 | 6.13 | |
EV/EBITDA |
60.80 | 68.01 | 53.72 | 74.82 | |
EV/Operating CF |
29.12 | 30.53 | 24.40 | 32.61 | |
EV/FCF |
32.85 | 34.50 | 31.70 | 68.39 | |
Quick Ratio |
4.61 | 4.53 | 4.62 | 4.52 | |
Current Ratio |
5.13 | 5.04 | 5.18 | 5.03 | |
Net Debt/EBITDA |
0.00 | (40.05) | 30.47 | (5.37) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.67 | 0.65 | 0.64 | 0.60 | |
Operating CF/Net income |
1.25 | 7.34 | (2.60) | 0.65 | |
Capex/Depreciation |
0.00 | (0.53) | (0.38) | (0.68) | |
Interest Coverage |
76.16 | 2.71 | (50.40) | 138.36 | |
Research and Development Expense of Revenue |
8.06% | 9.67% | 11.84% | 7.81% | |
Selling, General and Administrative Expense of Revenue |
51.00% | 62.58% | 71.94% | 46.77% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
9.16% | 11.73% | 16.51% | 9.06% | |
Graham Net Nets |
0.07 | 0.06 | 0.07 | 0.06 | |
Graham Number |
10.56 | 8.85 | 8.24 | 7.12 | |
Earnings Yield |
1.64% | 1.08% | 1.34% | 0.89% | |
Free Cash Flow Yield |
2.82% | 2.71% | 2.91% | 1.37% | |
Revenue per Share |
1.67 | 1.52 | 1.35 | 1.85 | |
Operating CF per Share |
0.35 | 0.32 | 0.32 | 0.30 | |
Capex per Share |
(0.04) | (0.04) | (0.02) | (0.04) | |
Free Cash Flow per Share |
0.31 | 0.28 | 0.30 | 0.25 | |
Cash per Share |
3.33 | 3.18 | 2.86 | 2.73 | |
Shareholders Equity per Share |
7.51 | 7.25 | 7.02 | 7.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.51 | 7.25 | 7.02 | 7.04 | |
Free Cash Flow |
15.68 | 14.26 | 15.13 | 12.83 | |
Working Capital |
226.05 | 212.20 | 196.91 | 198.29 | |
Capital Expenditures |
(2.04) | (1.93) | (1.26) | (2.19) | |
Net Current Asset Value |
147.83 | 131.91 | 114.67 | 114.11 | |
EV/EBIT |
70.51 | 116.65 | 95.44 | 153.25 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
76.18 | 124.61 | 103.56 | 164.14 | |
| Other line items | |||||
Average Receivables |
71.11 | 70.00 | 62.64 | 73.00 | |
Average Payables |
17.65 | 16.74 | 17.88 | 19.84 | |
Average Inventory |
17.61 | 17.61 | 17.73 | 17.47 | |
Average Assets |
485.19 | 469.24 | 455.11 | 460.35 | |
Average Common Equity |
353.02 | 338.43 | 325.86 | 323.30 |
Columns are period end dates · fundamentals updated 5 Nov 2026